What's next in psoriatic arthritis therapy? A look at the pipeline - PubMed
6 hours ago
- #therapeutic-pipeline
- #interleukin-17
- #psoriatic-arthritis
- Psoriatic arthritis (PsA) outcomes have improved, but many patients still lack sustained control, and some develop difficult-to-treat disease.
- New therapies in the PsA pipeline include IL-17 pathway advances (dual IL-17A/IL-17F blockade, engineered formats), selective tyrosine kinase 2 inhibition, and oral IL-23 receptor antagonism.
- Emerging strategies involve dual-targeted approaches for refractory PsA, metabolic targeting (e.g., incretin-based therapy), and disease interception in at-risk psoriasis patients.
- Future PsA care will focus on smarter strategies: more oral/selective therapies, interception in high-risk groups, metabolic integration, and optimized sequencing/combination therapy.